Research gaps in psoriasis: Opportunities for future studies

Journal of the American Academy of Dermatology

Volumn 70, Issue 1, 2014, Pages 146-167

  Ryan, Caitriona ^a   Korman, Neil J ^b   Gelfand, Joel M ^c   Lim, Henry W ^d   Elmets, Craig A ^e   Feldman, Steven R ^f   Gottlieb, Alice B ^g   Koo, John Y M ^h   Lebwohl, Mark ⁱ   Leonardi, Craig L ^j   Van Voorhees, Abby S ^c   Bhushan, Reva ^k   Menter, Alan ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d HENRY FORD HOSPITAL   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f WAKE FOREST SCHOOL OF MEDICINE   (United States)

^g TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^j SAINT LOUIS UNIVERSITY   (United States)

^k AMERICAN ACADEMY OF DERMATOLOGY   (United States)

more..

Author keywords

adjunctive therapies; biologics; cardiovascular disease; comorbidities in psoriasis; comparative studies; disease severity; environmental factors in the development of psoriasis; future research studies; methotrexate; molecular studies in psoriatic and psoriatic arthritis; pathomechanisms and genetics of psoriasis; phototherapy; psoriasis; psoriasis guidelines; psoriasis treatment; psoriatic arthritis; psychological; research gaps; therapeutic targets; topical therapies

Indexed keywords

AMINOPTERIN; CALCINEURIN INHIBITOR; CORTICOSTEROID; INFLIXIMAB; METHOTREXATE; VITAMIN D DERIVATIVE;

ARTICLE; CARDIOMETABOLIC RISK; CLINICAL RESEARCH; COMORBIDITY; GENE; GENETIC SUSCEPTIBILITY; HEALTH ECONOMICS; HUMAN; PERSONALIZED MEDICINE; PHOTOTHERAPY; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS;

EID: 84890797580     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2013.08.042     Document Type: Article

References (193)

1. A. Menter, A. Gottlieb, S.R. Feldman, A.S. Van Voorhees, C.L. Leonardi, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics J Am Acad Dermatol 58 2008 826 850
2. A. Menter, N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: section 4. Guidelines of care for the management and treatment of psoriasis with traditional systemic agents J Am Acad Dermatol 61 2009 451 485
3. A. Menter, N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies J Am Acad Dermatol 60 2009 643 659
4. A. Menter, N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 5. Guidelines of care for the treatment of psoriasis with phototherapy and photochemotherapy J Am Acad Dermatol 62 2010 114 135
5. A. Menter, N.J. Korman, C.A. Elmets, S.R. Feldman, J.M. Gelfand, and K.B. Gordon Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions J Am Acad Dermatol 65 2011 137 174
6. A. Gottlieb, N.J. Korman, K.B. Gordon, S.R. Feldman, M. Lebwohl, and J.Y. Koo Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics J Am Acad Dermatol 58 2008 851 864
7. R. Parisi, D.P. Symmons, C.E. Griffiths, D.M. Ashcroft team obotIaMoPaACIp Global Epidemiology of Psoriasis: A systematic review of incidence and prevalence J Invest Dermatol 133 2013 377 385
8. J.M. Gelfand, A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, and A.B. Troxel Risk of myocardial infarction in patients with psoriasis JAMA 296 2006 1735 1741
9. E.M. Farber, and M.L. Nall The natural history of psoriasis in 5,600 patients Dermatologica 148 1974 1 18
10. C.G. Helmick, J.J. Sacks, J.M. Gelfand, B. Bebo, H. Lee-Han, and T. Baird Psoriasis and psoriatic arthritis: a public health agenda Am J Prev Med 44 2013 424 426
11. T.E. Christensen, K.P. Callis, J. Papenfuss, M.S. Hoffman, C.B. Hansen, and B. Wong Observations of psoriasis in the absence of therapeutic intervention identifies two unappreciated morphologic variants, thin-plaque and thick-plaque psoriasis, and their associated phenotypes J Invest Dermatol 126 2006 2397 2403
12. R.P. Nair, K.C. Duffin, C. Helms, J. Ding, P.E. Stuart, and D. Goldgar Genome-wide scan reveals association of psoriasis with IL-23 and NF-kappaB pathways Nat Genet 41 2009 199 204
13. E. Riveira-Munoz, S.M. He, G. Escaramís, P.E. Stuart, U. Hüffmeier, and C. Lee Meta-analysis confirms the LCE3C-LCE3B deletion as a risk factor for psoriasis in several ethnic groups and finds interaction with HLA-Cw6 J Invest Dermatol 131 2011 1105 1109
14. P.E. Stuart, R.P. Nair, E. Ellinghaus, J. Ding, T. Tejasvi, and J.E. Gudjonsson Genome-wide association analysis identifies three psoriasis susceptibility loci Nat Genet 42 2010 1000 1004
15. J.T. Elder, A.T. Bruce, J.E. Gudjonsson, A. Johnston, P.E. Stuart, and T. Tejasvi Molecular dissection of psoriasis: integrating genetics and biology J Invest Dermatol 130 2010 1213 1226
16. A. Strange, F. Capon, C.C. Spencer, J. Knight, M.E. Weale, and M.H. Allen A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1 Nat Genet 42 2010 985 990
17. L.C. Tsoi, S.L. Spain, J. Knight, E. Ellinghaus, P.E. Stuart, and F. Capon Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity Nat Genet 44 2012 1341 1348
18. R. de Cid, E. Riveira-Munoz, P.L. Zeeuwen, J. Robarge, W. Liao, and E.N. Dannhauser Deletion of the late cornified envelope LCE3B and LCE3C genes as a susceptibility factor for psoriasis Nat Genet 41 2009 211 215
19. C.E. Griffiths Psoriasis: future research needs and goals for the twenty-first century Dermatol Clin 22 2004 493 499 x
20. S. Marrakchi, P. Guigue, B.R. Renshaw, A. Puel, X.Y. Pei, and S. Fraitag Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis N Engl J Med 365 2011 620 628
21. V. Chandran, C.T. Schentag, J.E. Brockbank, F.J. Pellett, S. Shanmugarajah, and S.M. Toloza Familial aggregation of psoriatic arthritis Ann Rheum Dis 68 2009 664 667
22. D.D. O'Rielly, and P. Rahman Genetics of susceptibility and treatment response in psoriatic arthritis Nat Rev Rheumatol 7 2011 718 732
23. E. Ellinghaus, D. Ellinghaus, P.E. Stuart, R.P. Nair, S. Debrus, and J.V. Raelson Genome-wide association study identifies a psoriasis susceptibility locus at TRAF3IP2 Nat Genet 42 2010 991 995
24. V. Chandran, and P. Rahman Update on the genetics of spondyloarthritis- ankylosing spondylitis and psoriatic arthritis Best Pract Res Clin Rheumatol 24 2010 579 588
25. Przepiera-Bedzak H, Ciechanowicz A, Brzosko I, MB. Influence of VEGF gene polymorphisms on clinical features of psoriatic arthritis and SAPHO syndrome [abstract]. 3rd World Congress of Psoriasis and Psoriatic Arthritis. Stockholm, Sweden June 28-30, 2012.
26. Chandran V, Cook R, Thavaneswaran A, Lee K, Fawnda PDG. Time to event and progressive multi-state analyses confirm the association between human leukocyte antigen alleles and the development of arthritis mutilans in patients with psoriatic arthritis [abstract]. 3rd World Congress of Psoriasis and Psoriatic Arthritis. Stockholm, Sweden, June 28-30, 2012.
27. F.O. Nestle, D.H. Kaplan, and J. Barker Psoriasis N Engl J Med 361 2009 496 509
28. H.J. Bovenschen, P.C. van de Kerkhof, P.E. van Erp, R. Woestenenk, I. Joosten, and H.J. Koenen Foxp3+ Regulatory T Cells of Psoriasis Patients Easily Differentiate into IL-17A-Producing Cells and Are Found in Lesional Skin J Invest Dermatol 131 2011 1853 1860
29. J. Fuentes-Duculan, M. Suárez-Fariñas, L.C. Zaba, K.E. Nograles, K.C. Pierson, and H. Mitsui A subpopulation of CD163-positive macrophages is classically activated in psoriasis J Invest Dermatol 130 2010 2412 2422
30. W.A. Goodman, A.D. Levine, J.V. Massari, H. Sugiyama, T.S. McCormick, and K.D. Cooper IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells J Immunol 183 2009 3170 3176
31. A.S. Haider, M.A. Lowes, M. Suárez-Fariñas, L.C. Zaba, I. Cardinale, and A. Khatcherian Identification of cellular pathways of «type 1,» Th17 T cells, and TNF- and inducible nitric oxide synthase-producing dendritic cells in autoimmune inflammation through pharmacogenomic study of cyclosporine A in psoriasis J Immunol 180 2008 1913 1920
32. E.M. Farber, S.W. Lanigan, and G. Rein The role of psychoneuroimmunology in the pathogenesis of psoriasis Cutis 46 1990 314 316
33. C.E. Joyce, X. Zhou, J. Xia, C. Ryan, B. Thrash, and A. Menter Deep sequencing of small RNAs from human skin reveals major alterations in the psoriasis miRNAome Hum Mol Genet 2011
34. E.D. Roberson, Y. Liu, C. Ryan, C.E. Joyce, S. Duan, and L. Cao A subset of methylated CpG sites differentiate psoriatic from normal skin J Invest Dermatol 132 2012 583 592
35. M. Detmar, L.F. Brown, K.P. Claffey, K.T. Yeo, O. Kocher, and R.W. Jackman Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis J Exp Med 180 1994 1141 1146
36. M. Detmar The role of VEGF and thrombospondins in skin angiogenesis J Dermatol Sci 24 Suppl 1 2000 S78 S84
37. A. Henno, S. Blacher, C. Lambert, A. Colige, L. Seidel, and A. Noël Altered expression of angiogenesis and lymphangiogenesis markers in the uninvolved skin of plaque-type psoriasis Br J Dermatol 160 2009 581 590
38. C. Halin, H. Fahrngruber, J.G. Meingassner, G. Bold, A. Littlewood-Evans, and A. Stuetz Inhibition of chronic and acute skin inflammation by treatment with a vascular endothelial growth factor receptor tyrosine kinase inhibitor Am J Pathol 173 2008 265 277
39. A. Akman, E. Yilmaz, H. Mutlu, and M. Ozdogan Complete remission of psoriasis following bevacizumab therapy for colon cancer Clin Exp Dermatol 34 2009 e202 e204
40. C. Ryan, and B. Kirby Neuropeptides and psoriasis G Ital Dermatol Venereol 142 2007 479 488
41. H.L. Richards, D.W. Ray, B. Kirby, D. Mason, D. Plant, and C.J. Main Response of the hypothalamic-pituitary-adrenal axis to psychological stress in patients with psoriasis Br J Dermatol 153 2005 1114 1120
42. E.M. Farber, B.J. Nickoloff, B. Recht, and J.E. Fraki Stress, symmetry, and psoriasis: possible role of neuropeptides J Am Acad Dermatol 14 1986 305 311
43. M. Kono, H. Nagata, S. Umemura, S. Kawana, and R.Y. Osamura In situ expression of corticotropin-releasing hormone (CRH) and proopiomelanocortin (POMC) genes in human skin FASEB J 15 2001 2297 2299
44. M. O'Kane, E.P. Murphy, and B. Kirby The role of corticotropin-releasing hormone in immune-mediated cutaneous inflammatory disease Exp Dermatol 15 2006 143 153
45. A. Slominski, J. Wortsman, T. Luger, R. Paus, and S. Solomon Corticotropin releasing hormone and proopiomelanocortin involvement in the cutaneous response to stress Physiol Rev 80 2000 979 1020
46. T. Joseph, J. Kurian, D.J. Warwick, and P.S. Friedmann Unilateral remission of psoriasis following traumatic nerve palsy Br J Dermatol 152 2005 185 186
47. E.M. Farber, S.W. Lanigan, and J. Boer The role of cutaneous sensory nerves in the maintenance of psoriasis Int J Dermatol 29 1990 418 420
48. S.M. Ostrowski, A. Belkadi, C.M. Loyd, D. Diaconu, and N.L. Ward Cutaneous denervation of psoriasiform mouse skin improves acanthosis and inflammation in a sensory neuropeptide-dependent manner J Invest Dermatol 131 2011 1530 1538
49. S.M. Behnam, S.E. Behnam, and J.Y. Koo Smoking and psoriasis Skinmed 4 2005 174 176
50. C. Fortes, S. Mastroeni, K. Leffondré, F. Sampogna, F. Melchi, and E. Mazzotti Relationship between smoking and the clinical severity of psoriasis Arch Dermatol 141 2005 1580 1584
51. K. Poikolainen, J. Karvonen, and E. Pukkala Excess mortality related to alcohol and smoking among hospital-treated patients with psoriasis Arch Dermatol 135 1999 1490 1493
52. K. Wolk, L. Mallbris, P. Larsson, A. Rosenblad, E. Vingård, and M. Ståhle Excessive body weight and smoking associates with a high risk of onset of plaque psoriasis Acta Derm Venereol 89 2009 492 497
53. K. Torii, C. Saito, T. Furuhashi, A. Nishioka, Y. Shintani, and K. Kawashima Tobacco smoke is related to Th17 generation with clinical implications for psoriasis patients Exp Dermatol 20 2011 371 373
54. M.A. McAleer, D.L. Mason, S. Cunningham, S.J. O'Shea, P.A. McCormick, and C. Stone Alcohol misuse in patients with psoriasis: identification and relationship to disease severity and psychological distress Br J Dermatol 164 2011 1256 1261
55. C.A. Janeway, and R. Medzhitov Innate immune recognition Annu Rev Immunol 20 2002 197 216
56. R. Lande, J. Gregorio, V. Facchinetti, B. Chatterjee, Y.H. Wang, and B. Homey Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide Nature 449 2007 564 569
57. J.C. Prinz Psoriasis vulgaris-a sterile antibacterial skin reaction mediated by cross-reactive T cells? An immunological view of the pathophysiology of psoriasis Clin Exp Dermatol 26 2001 326 332
58. J.C. Prinz Disease mimicry-a pathogenetic concept for T cell-mediated autoimmune disorders triggered by molecular mimicry? Autoimmun Rev 3 2004 10 15
59. J.P. McFadden, B.S. Baker, A.V. Powles, and L. Fry Psoriasis and streptococci: the natural selection of psoriasis revisited Br J Dermatol 160 2009 929 937
60. K. Krishnamurthy, A. Walker, C.A. Gropper, and C. Hoffman To treat or not to treat? Management of guttate psoriasis and pityriasis rosea in patients with evidence of group A Streptococcal infection J Drugs Dermatol 9 2010 241 250
61. A. Fahlén, L. Engstrand, B.S. Baker, A. Powles, and L. Fry Comparison of bacterial microbiota in skin biopsies from normal and psoriatic skin Arch Dermatol Res 304 2012 15 22
62. Z. Gao, C.H. Tseng, B.E. Strober, Z. Pei, and M.J. Blaser Substantial alterations of the cutaneous bacterial biota in psoriatic lesions PLoS One 3 2008 e2719
63. L. Fry, B.S. Baker, A.V. Powles, A. Fahlen, and L. Engstrand Is chronic plaque psoriasis triggered by microbiota in the skin? Br J Dermatol 169 2013 47 52
64. F.P. Siegal, N. Kadowaki, M. Shodell, P.A. Fitzgerald-Bocarsly, K. Shah, and S. Ho The nature of the principal type 1 interferon-producing cells in human blood Science 284 1999 1835 1837
65. N. Kadowaki, S. Ho, S. Antonenko, R.W. Malefyt, R.A. Kastelein, and F. Bazan Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens J Exp Med 194 2001 863 869
66. T.P. Korzhova, V.P. Shyrobokov, V.H. Koliadenko, O.M. Korniushenko, N.V. Akhramieieva, and V.I. Stepanenko Coxsackie B viral infection in the etiology and clinical pathogenesis of psoriasis Lik Sprava 2001 54 58
67. H. Chen, G. Hayashi, O.Y. Lai, A. Dilthey, P.J. Kuebler, and T.V. Wong Psoriasis patients are enriched for genetic variants that protect against HIV-1 disease PLoS Genet 8 2012 e1002514
68. B.J. Nickoloff, and T. Wrone-Smith Injection of pre-psoriatic skin with CD4+ T cells induces psoriasis Am J Pathol 155 1999 145 158
69. O. Boyman, H.P. Hefti, C. Conrad, B.J. Nickoloff, M. Suter, and F.O. Nestle Spontaneous development of psoriasis in a new animal model shows an essential role for resident T cells and tumor necrosis factor-alpha J Exp Med 199 2004 731 736
70. A.S. Paller, K. Mercy, M.J. Kwasny, S.E. Choon, K.M. Cordoro, and G. Girolomoni Association of pediatric psoriasis severity with excess and central adiposity: an international cross-sectional study JAMA Dermatol 149 2013 166 176
71. A.B. Kimball, E.Q. Wu, A. Guérin, A.P. Yu, M. Tsaneva, and S.R. Gupta Risks of developing psychiatric disorders in pediatric patients with psoriasis J Am Acad Dermatol 67 2012 651 657.e1-2
72. A.S. Paller, E.C. Siegfried, R.G. Langley, A.B. Gottlieb, D. Pariser, and I. Landells Etanercept treatment for children and adolescents with plaque psoriasis N Engl J Med 358 2008 241 251
73. A.S. Paller, E.C. Siegfried, L.F. Eichenfield, D. Pariser, R.G. Langley, and K. Creamer Long-term etanercept in pediatric patients with plaque psoriasis J Am Acad Dermatol 63 2010 762 768
74. R.L. Gorman The march toward rational therapeutics in children Pediatr Infect Dis J 22 2003 1119 1123
75. A. Zajicek The National Institutes of Health and the Best Pharmaceuticals for Children Act Paediatr Drugs 11 2009 45 47
76. L.B. Finer, and M.R. Zolna Unintended pregnancy in the United States: incidence and disparities, 2006 Contraception 84 2011 478 485
77. J.E. Murase, K.K. Chan, T.J. Garite, D.M. Cooper, and G.D. Weinstein Hormonal effect on psoriasis in pregnancy and post partum Arch Dermatol 141 2005 601 606
78. G. Ben-David, E. Sheiner, M. Hallak, and A. Levy Pregnancy outcome in women with psoriasis J Reprod Med 53 2008 183 187
79. Y.S. Bae, A.S. Van Voorhees, S. Hsu, N.J. Korman, M.G. Lebwohl, and M. Young Review of treatment options for psoriasis in pregnant or lactating women: from the Medical Board of the National Psoriasis Foundation J Am Acad Dermatol 67 2012 459 477
80. E.J. Horn, C.D. Chambers, A. Menter, A.B. Kimball, and I.P. Council Pregnancy outcomes in psoriasis: why do we know so little? J Am Acad Dermatol 61 2009 e5 e8
81. J. Lam, J.E. Polifka, and M.A. Dohil Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases J Am Acad Dermatol 59 2008 295 315
82. C.C. Chi, C.W. Lee, F. Wojnarowska, and G. Kirtschig Safety of topical corticosteroids in pregnancy Cochrane Database Syst Rev 2009 CD007346
83. C.C. Chi, G. Kirtschig, W. Aberer, J.P. Gabbud, J. Lipozenč ić, and S. Kárpáti Evidence-based (S3) guideline on topical corticosteroids in pregnancy Br J Dermatol 165 2011 943 952
84. C.C. Chi, R.T. Mayon-White, and F.T. Wojnarowska Safety of topical corticosteroids in pregnancy: a population-based cohort study J Invest Dermatol 131 2011 884 891
85. M.J. Edwards, K. Agho, J. Attia, P. Diaz, T. Hayes, and A. Illingworth Case-control study of cleft lip or palate after maternal use of topical corticosteroids during pregnancy Am J Med Genet A 120A 2003 459 463
86. M. Petri Immunosuppressive drug use in pregnancy Autoimmunity 36 2003 51 56
87. V. Lamarque, M.F. Leleu, C. Monka, and P. Krupp Analysis of 629 pregnancy outcomes in transplant recipients treated with Sandimmun Transplant Proc 29 1997 2480
88. B. Bar Oz, R. Hackman, T. Einarson, and G. Koren Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis Transplantation 71 2001 1051 1055
89. J.D. Carter, A. Ladhani, L.R. Ricca, J. Valeriano, and F.B. Vasey A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database J Rheumatol 36 2009 635 641
90. J.A. Katz, C. Antoni, G.F. Keenan, D.E. Smith, S.J. Jacobs, and G.R. Lichtenstein Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis Am J Gastroenterol 99 2004 2385 2392
91. E.E. Winger, and J.L. Reed Was risk properly assessed in Carter, et al's safety assessment of tumor necrosis factor antagonists during pregnancy? J Rheumatol 36 2009 2122 author reply 2123
92. K. Cheent, J. Nolan, S. Shariq, L. Kiho, A. Pal, and J. Arnold Case Report: Fatal case of disseminated BCG infection in an infant born to a mother taking infliximab for Crohn's disease J Crohns Colitis 4 2010 603 605
93. A. Murashima, N. Watanabe, N. Ozawa, H. Saito, and K. Yamaguchi Etanercept during pregnancy and lactation in a patient with rheumatoid arthritis: drug levels in maternal serum, cord blood, breast milk and the infant's serum Ann Rheum Dis 68 2009 1793 1794
94. B.G. Berthelsen, H. Fjeldsøe-Nielsen, C.T. Nielsen, and E. Hellmuth Etanercept concentrations in maternal serum, umbilical cord serum, breast milk and child serum during breastfeeding Rheumatology (Oxford) 49 2010 2225 2227
95. Stelara Prescribing Information. Available at: http://www.stelarainfo. com/pdf/PrescribingInformation.pdf.%C2%A0Last. Accessed June 21, 2012.
96. R. Andrulonis, and L.K. Ferris Treatment of severe psoriasis with ustekinumab during pregnancy J Drugs Dermatol 11 2012 1240
97. G. Nyberg, U. Haljamäe, C. Frisenette-Fich, M. Wennergren, and I. Kjellmer Breast-feeding during treatment with cyclosporine Transplantation 65 1998 253 255
98. D.S. Mishkin, W. Van Deinse, J.M. Becker, and F.A. Farraye Successful use of adalimumab (Humira) for Crohn's disease in pregnancy Inflamm Bowel Dis 12 2006 827 828
99. E.A. Vasiliauskas, J.A. Church, N. Silverman, M. Barry, S.R. Targan, and M.C. Dubinsky Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn Clin Gastroenterol Hepatol 4 2006 1255 1258
100. C.L. Kauffman, N. Aria, E. Toichi, T.S. McCormick, K.D. Cooper, and A.B. Gottlieb A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis J Invest Dermatol 123 2004 1037 1044
101. J.O. Endo, J.W. Wong, R.A. Norman, and A.L. Chang Geriatric dermatology: Part I. Geriatric pharmacology for the dermatologist J Am Acad Dermatol 68 2013 521.e1-10; quiz 31-2
102. I.S. Grozdev, A.S. Van Voorhees, A.B. Gottlieb, S. Hsu, M.G. Lebwohl, and B.F. Bebo Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation J Am Acad Dermatol 65 2011 537 545
103. K.E. Nograles, R.D. Brasington, and A.M. Bowcock New insights into the pathogenesis and genetics of psoriatic arthritis Nat Clin Pract Rheumatol 5 2009 83 91
104. D.D. Gladman, C. Antoni, P. Mease, D.O. Clegg, and P. Nash Psoriatic arthritis: epidemiology, clinical features, course, and outcome Ann Rheum Dis 64 Suppl 2 2005 ii14 ii17
105. E. Theander, T. Husmark, G.M. Alenius, P.T. Larsson, A. Teleman, and M. Geijer Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA) Ann Rheum Dis 2013 Jan 25. [Epub ahead of print]
106. Kirkham B, Li W, Boggs R, Nab H, Tarallo M. Early treatment of psoriatic arthritis is associated with improved outcomes: findings from the etanercept PRESTA trial [abstract]. 3rd World Congress of Psoriasis and Psoriatic Arthritis. Stockholm, Sweden, June 28-30, 2012.
107. P. Lloyd, C. Ryan, and A. Menter Psoriatic arthritis: an update Arthritis 2012 2012 176298
108. M. Haroon, B. Kirby, and O. FitzGerald High prevalence of psoriatic arthritis in patients with severe psoriasis with suboptimal performance of screening questionnaires Ann Rheum Dis 72 2013 736 740
109. Korotaeva T, Krasnenko S, Loginova E, Goryachev D, Smirnov A. Clinical examination versus magnetic resonance imaging of the hand and foot: its usefulness in early detection of psoriatic arthritis among patients with psoriasis [abstract]. 3rd World Congress of Psoriasis and Psoriatic Arthritis. Stockholm, Sweden, June 28-30, 2012.
110. A.L. Neimann, D.B. Shin, X. Wang, D.J. Margolis, A.B. Troxel, and J.M. Gelfand Prevalence of cardiovascular risk factors in patients with psoriasis J Am Acad Dermatol 55 2006 829 835
111. A. Menter, C.E. Griffiths, P.W. Tebbey, E.J. Horn, W. Sterry, and I.P. Council Exploring the association between cardiovascular and other disease-related risk factors in the psoriasis population: the need for increased understanding across the medical community J Eur Acad Dermatol Venereol 24 2010 1371 1377
112. A.M. Tobin, R. Hughes, E.B. Hand, T. Leong, I.M. Graham, and B. Kirby Homocysteine status and cardiovascular risk factors in patients with psoriasis: a case-control study Clin Exp Dermatol 36 2011 19 23
113. J.M. Gelfand, A.B. Troxel, J.D. Lewis, S.K. Kurd, D.B. Shin, and X. Wang The risk of mortality in patients with psoriasis: results from a population-based study Arch Dermatol 143 2007 1493 1499
114. M. Wakkee, R.M. Herings, and T. Nijsten Psoriasis may not be an independent risk factor for acute ischemic heart disease hospitalizations: results of a large population-based Dutch cohort J Invest Dermatol 130 2010 962 967
115. R.S. Stern, and A. Huibregtse Very severe psoriasis is associated with increased noncardiovascular mortality but not with increased cardiovascular risk J Invest Dermatol 131 2011 1159 1166
116. J.M. Gelfand, N.N. Mehta, and S.M. Langan Psoriasis and cardiovascular risk: strength in numbers, part II J Invest Dermatol 131 2011 1007 1010
117. T. Henseler, and E. Christophers Disease concomitance in psoriasis J Am Acad Dermatol 32 1995 982 986
118. A.R. Setty, G. Curhan, and H.K. Choi Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II Arch Intern Med 167 2007 1670 1675
119. L. Mallbris, F. Granath, A. Hamsten, and M. Ståhle Psoriasis is associated with lipid abnormalities at the onset of skin disease J Am Acad Dermatol 54 2006 614 621
120. M.D. Herron, M. Hinckley, M.S. Hoffman, J. Papenfuss, C.B. Hansen, and K.P. Callis Impact of obesity and smoking on psoriasis presentation and management Arch Dermatol 141 2005 1527 1534
121. A.A. Qureshi, H.K. Choi, A.R. Setty, and G.C. Curhan Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses Arch Dermatol 145 2009 379 382
122. R.S. Azfar, N.M. Seminara, D.B. Shin, A.B. Troxel, D.J. Margolis, and J.M. Gelfand Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis Arch Dermatol 148 2012 995 1000
123. D.M. Sommer, S. Jenisch, M. Suchan, E. Christophers, and M. Weichenthal Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis Arch Dermatol Res 298 2006 321 328
124. B.B. Davidovici, N. Sattar, J.C. Prinz, P.C. Jörg, L. Puig, and P. Emery Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions J Invest Dermatol 130 2010 1785 1796
125. W.H. Boehncke, S. Boehncke, A.M. Tobin, and B. Kirby The 'psoriatic march': a concept of how severe psoriasis may drive cardiovascular comorbidity Exp Dermatol 20 2011 303 307
126. C. Ryan, and A. Menter Psoriasis and cardiovascular disorders G Ital Dermatol Venereol 147 2012 179 187
127. P. Gisondi, and G. Girolomoni Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors Semin Thromb Hemost 35 2009 313 324
128. A.W. Armstrong, S.V. Voyles, E.J. Armstrong, E.N. Fuller, and J.C. Rutledge Angiogenesis and oxidative stress: common mechanisms linking psoriasis with atherosclerosis J Dermatol Sci 63 2011 1 9
129. V.E. Friedewald, J.C. Cather, J.M. Gelfand, K.B. Gordon, G.H. Gibbons, and S.M. Grundy AJC editor's consensus: psoriasis and coronary artery disease Am J Cardiol 102 2008 1631 1643
130. S. Prodanovich, S. Prodanowich, F. Ma, J.R. Taylor, C. Pezon, and T. Fasihi Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis J Am Acad Dermatol 52 2005 262 267
131. S. Boehncke, R. Salgo, J. Garbaraviciene, H. Beschmann, K. Hardt, and S. Diehl Effective continuous systemic therapy of severe plaque-type psoriasis is accompanied by amelioration of biomarkers of cardiovascular risk: results of a prospective longitudinal observational study J Eur Acad Dermatol Venereol 25 2011 1187 1193
132. J.J. Wu, K.Y. Poon, J.C. Channual, and A.Y. Shen Association Between Tumor Necrosis Factor Inhibitor Therapy and Myocardial Infarction Risk in Patients With Psoriasis Arch Dermatol 2012 1 7
133. S. Boehncke, S. Fichtlscherer, R. Salgo, J. Garbaraviciene, H. Beschmann, and S. Diehl Systemic therapy of plaque-type psoriasis ameliorates endothelial cell function: results of a prospective longitudinal pilot trial Arch Dermatol Res 303 2011 381 388
134. B. Strober, C. Teller, P. Yamauchi, J.L. Miller, M. Hooper, and Y.C. Yang Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis Br J Dermatol 159 2008 322 330
135. D.H. Solomon, E. Massarotti, R. Garg, J. Liu, C. Canning, and S. Schneeweiss Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis JAMA 305 2011 2525 2531
136. C. Ryan, C.L. Leonardi, J.G. Krueger, A.B. Kimball, B.E. Strober, and K.B. Gordon Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials JAMA 306 2011 864 871
137. T. Tzellos, A. Kyrgidis, and C.C. Zouboulis Re-evaluation of the risk for major adverse cardiovascular events in patients treated with anti-IL-12/23 biological agents for chronic plaque psoriasis: a meta-analysis of randomized controlled trials J Eur Acad Dermatol Venereol 27 2013 622 627
138. E.D. Dommasch, A.B. Troxel, and J.M. Gelfand Major cardiovascular events associated with anti-IL 12/23 agents: A tale of two meta-analyses J Am Acad Dermatol 68 2013 863 865
139. S. Greenland, and A. Salvan Bias in the one-step method for pooling study results Stat Med 9 1990 247 252
140. K.A. Papp, C.E. Griffiths, K. Gordon, M. Lebwohl, P.O. Szapary, and Y. Wasfi Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up Br J Dermatol 168 2013 844 854
141. G. Higa-Sansone, S. Szomstein, F. Soto, O. Brasecsco, C. Cohen, and R.J. Rosenthal Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity Obes Surg 14 2004 1132 1134
142. M. Wolters Diet and psoriasis: experimental data and clinical evidence Br J Dermatol 153 2005 706 714
143. P. Gisondi, M. Del Giglio, V. Di Francesco, M. Zamboni, and G. Girolomoni Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial Am J Clin Nutr 88 2008 1242 1247
144. S.R. Rapp, S.R. Feldman, M.L. Exum, A.B. Fleischer, and D.M. Reboussin Psoriasis causes as much disability as other major medical diseases J Am Acad Dermatol 41 1999 401 407
145. G. Krueger, J. Koo, M. Lebwohl, A. Menter, R.S. Stern, and T. Rolstad The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey Arch Dermatol 137 2001 280 284
146. J.M. Schmitt, and D.E. Ford Work limitations and productivity loss are associated with health-related quality of life but not with clinical severity in patients with psoriasis Dermatology 213 2006 102 110
147. J.M. Schmitt, and D.E. Ford Role of depression in quality of life for patients with psoriasis Dermatology 215 2007 17 27
148. J. Schmitt, and D.E. Ford Understanding the relationship between objective disease severity, psoriatic symptoms, illness-related stress, health-related quality of life and depressive symptoms in patients with psoriasis - a structural equations modeling approach Gen Hosp Psychiatry 29 2007 134 140
149. S. Tyring, A. Gottlieb, K. Papp, K. Gordon, C. Leonardi, and A. Wang Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Lancet 367 2006 29 35
150. J. Kabat-Zinn, E. Wheeler, T. Light, A. Skillings, M.J. Scharf, and T.G. Cropley Influence of a mindfulness meditation-based stress reduction intervention on rates of skin clearing in patients with moderate to severe psoriasis undergoing phototherapy (UVB) and photochemotherapy (PUVA) Psychosom Med 60 1998 625 632
151. D.G. Fortune, H.L. Richards, B. Kirby, S. Bowcock, C.J. Main, and C.E. Griffiths A cognitive-behavioural symptom management programme as an adjunct in psoriasis therapy Br J Dermatol 146 2002 458 465
152. G. Schmid-Ott, H.W. Kuensebeck, B. Jaeger, T. Werfel, K. Frahm, and J. Ruitman Validity study for the stigmatization experience in atopic dermatitis and psoriatic patients Acta Derm Venereol 79 1999 443 447
153. S. Kapila, J. Bradford, and G. Fischer Vulvar psoriasis in adults and children: a clinical audit of 194 cases and review of the literature J Low Genit Tract Dis 16 2012 364 371
154. J.M. Gelfand, J. Wan, K. Callis Duffin, G.G. Krueger, R.E. Kalb, and J.D. Weisman Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice setting Arch Dermatol 148 2012 487 494
155. J.J. Miller, D. Roling, D. Margolis, and C. Guzzo Failure to demonstrate therapeutic tachyphylaxis to topically applied steroids in patients with psoriasis J Am Acad Dermatol 41 1999 546 549
156. R.M. Hearn, A.C. Kerr, K.F. Rahim, J. Ferguson, and R.S. Dawe Incidence of skin cancers in 3867 patients treated with narrow-band ultraviolet B phototherapy Br J Dermatol 159 2008 931 935
157. W. Edmundson, and W. Guy Treatment of psoriasis with folic acid antagonists AMA Arch Derm 78 1958 200 203
158. I. Flytström, B. Stenberg, A. Svensson, and I.M. Bergbrant Methotrexate vs. ciclosporin in psoriasis: effectiveness, quality of life and safety. A randomized controlled trial Br J Dermatol 158 2008 116 121
159. V.M. Heydendael, P.I. Spuls, B.C. Opmeer, C.A. de Borgie, J.B. Reitsma, and W.F. Goldschmidt Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis N Engl J Med 349 2003 658 665
160. R.E. Kalb, B. Strober, G. Weinstein, and M. Lebwohl Methotrexate and
161. H. Montaudié, E. Sbidian, C. Paul, A. Maza, A. Gallini, and S. Aractingi Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity J Eur Acad Dermatol Venereol 25 Suppl 2 2011 12 18
162. P. Gisondi, G. Targher, G. Zoppini, and G. Girolomoni Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis J Hepatol 51 2009 758 764
163. G.H. Kingsley, A. Kowalczyk, H. Taylor, F. Ibrahim, J.C. Packham, and N.J. McHugh A randomized placebo-controlled trial of methotrexate in psoriatic arthritis Rheumatology (Oxford) 51 2012 1368 1377
164. A. Baranauskaite, H. Raffayová, N.V. Kungurov, A. Kubanova, A. Venalis, and L. Helmle Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study Ann Rheum Dis 71 2012 541 548
165. R. Rees, and J. Bennett Psoriasis-chemotherapy with aminopterin and methotrexate Skin (Los Angeles) 1 1962 381 382
166. R. Rees, J. Bennett, E. Hamlin, and H. Maibach Aminopterin for psoriasis. A decade's observation Arch Dermatol 90 1964 544 552
167. P.D. Cole, J.A. Zebala, M.J. Alcaraz, A.K. Smith, J. Tan, and B.A. Kamen Pharmacodynamic properties of methotrexate and Aminotrexate during weekly therapy Cancer Chemother Pharmacol 57 2006 826 834
168. P.D. Cole, R.A. Drachtman, M. Masterson, A.K. Smith, J. Glod, and J.A. Zebala Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia Cancer Chemother Pharmacol 62 2008 65 75
169. A. Menter, B. Thrash, C. Cherian, L.H. Matherly, L. Wang, and A. Gangjee Intestinal transport of aminopterin enantiomers in dogs and humans with psoriasis is stereoselective: evidence for a mechanism involving the proton-coupled folate transporter J Pharmacol Exp Ther 342 2012 696 708
170. P.H. Conway, and C. Clancy Comparative-effectiveness research- implications of the Federal Coordinating Council's report N Engl J Med 361 2009 328 330
171. C.E. Griffiths, B.E. Strober, P. van de Kerkhof, V. Ho, R. Fidelus-Gort, and N. Yeilding Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis N Engl J Med 362 2010 118 128
172. C. Ryan, A. Abramson, M. Patel, and A. Menter Current investigational drugs in psoriasis Expert Opin Investig Drugs 21 2012 473 487
173. S.L. Wang, S. Hauenstein, L. Ohrmund, R. Shringarpure, J. Salbato, and R. Reddy Monitoring of adalimumab and antibodies-to-adalimumab levels in patient serum by the homogeneous mobility shift assay J Pharm Biomed Anal 78-79 2013 39 44
174. S.K. Mahil, Z. Arkir, G. Richards, C.M. Lewis, J.N. Barker, and C.H. Smith Predicting treatment response in psoriasis using serum levels of adalimumab and etanercept: a single-centre, cohort study Br J Dermatol 169 2013 306 313
175. Garcês S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis doi:10.1136/annrheumdis- 2012-202220. Published online December 6, 2012.
176. C. Ryan, A. Menter, and R.B. Warren The latest advances in pharmacogenetics and pharmacogenomics in the treatment of psoriasis Mol Diagn Ther 14 2010 81 93
177. R.B. Warren, R.L. Smith, E. Campalani, S. Eyre, C.H. Smith, and J.N. Barker Genetic variation in efflux transporters influences outcome to methotrexate therapy in patients with psoriasis J Invest Dermatol 128 2008 1925 1929
178. H.S. Young, A.M. Summers, I.R. Read, D.A. Fairhurst, D.J. Plant, and E. Campalani Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis J Invest Dermatol 126 2006 453 459
179. T. Tejasvi, P.E. Stuart, V. Chandran, J.J. Voorhees, D.D. Gladman, and P. Rahman TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis J Invest Dermatol 132 2012 593 600
180. A.S. Haider, M.A. Lowes, H. Gardner, R. Bandaru, K. Darabi, and F. Chamian Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients J Immunol 178 2007 7442 7449
181. M. Suárez-Fariñas, K.R. Shah, A.S. Haider, J.G. Krueger, and M.A. Lowes Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept BMC Dermatol 10 2010 1
182. F.B. Vincent, E.F. Morand, K. Murphy, F. Mackay, X. Mariette, and C. Marcelli Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective Ann Rheum Dis 72 2013 165 178
183. E.D. Dommasch, K. Abuabara, D.B. Shin, J. Nguyen, A.B. Troxel, and J.M. Gelfand The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials J Am Acad Dermatol 64 2011 1035 1050
184. L. Naldi, A. Addis, S. Chimenti, A. Giannetti, M. Picardo, and C. Tomino Impact of body mass index and obesity on clinical response to systemic treatment for psoriasis. Evidence from the Psocare project Dermatology 217 2008 365 373
185. V. Beyer, and S.E. Wolverton Recent trends in systemic psoriasis treatment costs Arch Dermatol 146 2010 46 54
186. D.W. Miller, and S.R. Feldman Cost-effectiveness of moderate-to-severe psoriasis treatment Expert Opin Pharmacother 7 2006 157 167
187. D. Palmer, and Y. El Miedany Biological nurse specialist: goodwill to good practice Br J Nurs 19 2010 477 480
188. D.J. Eedy, C.E. Griffiths, R.J. Chalmers, A.D. Ormerod, C.H. Smith, and J.N. Barker Care of patients with psoriasis: an audit of U.K. services in secondary care Br J Dermatol 160 2009 557 564
189. C. Gradwell, K.S. Thomas, J.S. English, and H.C. Williams A randomized controlled trial of nurse follow-up clinics: do they help patients and do they free up consultants' time? Br J Dermatol 147 2002 513 517
190. C. Riddoch The benefits of switching to nurse-led management of patients with psoriasis Prof Nurse 20 2005 38 40
191. J. Frühauf, G. Schwantzer, C.M. Ambros-Rudolph, W. Weger, V. Ahlgrimm-Siess, and W. Salmhofer Pilot study using teledermatology to manage high-need patients with psoriasis Arch Dermatol 146 2010 200 201
192. J. Frühauf, G. Schwantzer, C.M. Ambros-Rudolph, W. Weger, V. Ahlgrimm-Siess, and W. Salmhofer Pilot study on the acceptance of mobile teledermatology for the home monitoring of high-need patients with psoriasis Australas J Dermatol 53 2012 41 46
193. S. Koller, R. Hofmann-Wellenhof, D. Hayn, W. Weger, P. Kastner, and G. Schreier Teledermatological monitoring of psoriasis patients on biologic therapy Acta Derm Venereol 91 2011 680 685